We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Bead-Based Immunoassay Developed to Measure Vimentin Autoantibodies

By LabMedica International staff writers
Posted on 01 Jul 2014
Print article
Luminex FlexMap 3D
Multiplex assay (Photo courtesy of Luminex - A Diasorin Company)
An immunobead assay has been developed to quantitate circulating levels of vimentin antibodies, and, to test the feasibility of these autoantibodies as a biomarker for clinical diagnosis.

Vimentin is an intermediate filament protein generally expressed in the cytosol of many adult cell types, including leukocytes, fibroblasts and endothelial cells. Several tissue and/or injury-specific isoforms of vimentin are known to exist that may trigger autoimmune responses due to aberrant structural or conformational variations.

Scientists at the Rush University Medical Center (Chicago, IL, USA) evaluated the efficacy of the newly developed assay on discarded serum samples collected from 51 renal transplant patients with allograft dysfunction and compared the results with control specimens from 20 age and gender matched control individuals.

Magplex Microspheres (Luminex Corporation; Austin, TX, USA) were used in the development of this vimentin autoantibody assay and were processed in batches of 106 beads. Recombinant human vimentin (R&D Systems, Minneapolis, MN, USA) were added to the MagPlex beads and serum samples were processed. Assay performance and microsphere validation was accomplished by reading on a Luminex FlexMap 3-D system with a minimum of 50 bead reads per well. Median fluorescence intensity (MFI) values were reported for the conditions to permit the evaluation of coupling efficiency and preliminary evaluation of an assay range.

Preliminary evaluation of the assay demonstrates significantly higher circulating levels of anti-vimentin antibodies in 51 cases of renal allograft rejection relative to 20 cases of age-matched controls. From repeated testing of three distinct batches of assays provide assay range parameters of 0.18–15 μg/mL, median inter-assay recovery parameter was within 1% of completion, and interassay variation was at 7%.

The authors concluded that their direct capture assay for vimentin autoantibodies was successfully developed and analytically validated. Preliminary evaluation of this assay against patient materials was promising and justifies additional testing with larger cohorts in future studies. The study was published in the May 2014 issue of Journal of Immunological Methods.

Related Links:

Rush University Medical Center
Luminex Corporation
R&D Systems


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.